Background--Kruppel-like factor 2 (KLF2) is an important zinc-finger transcription factor that maintains endothelial homeostasis by its anti-inflammatory, -thrombotic, -oxidative, and -proliferative effects in endothelial cells. In light of the potent vasoprotective effects of KLF2, modulating KLF2 expression or function could give rise to new therapeutic strategies to treat cardiovascular diseases.
1 expression, and represses expression of adhesion molecules, such as vascular cell adhesion molecule 1 (VCAM1). 1, 8, 10 Experimental studies have demonstrated that shear stress 11 along with small molecules such as lipid-lowering statins 10, 12 and resveratrol are capable of exerting vasoprotective effects by promoting KLF2 activation. 4, 12, 13 The molecular mechanisms involved in the regulation of endothelial KLF2 expression includes the AMP-activated protein kinase/dual specificity mitogen-activated protein kinase kinase 5/extracellular-signal related kinase 5/MEF2 (myocyte enhancing factor 2) pathway and the histone deacetylase (HDAC) 5 pathway. 1, 14, 15 Recent studies have demonstrated that deletion of 1 KLF2 allele in mice increases atherosclerosis, 16 and KLF2 controls endothelial and vascular integrity. 17 These important findings suggest that KLF2 could serve as a promising therapeutic target for the treatment of atherosclerosis. In light of the potent vasoprotective effects mediated by KLF2, modulating KLF2 expression or function might be a novel therapeutic strategy for a wide range of human diseases, including cardiovascular diseases. 1 Therefore, we aimed to identify novel KLF2 activators using a luciferase assay based high-throughput drug screening and hoped that these activators would have endothelial protective functions. Interestingly, we have identified a US Food and Drug Administrationapproved small molecule, suberoylanilide hydroxamic acid (SAHA, also known as Vorinostat or MK0683), as a novel KLF2 activator, that prevents endothelial inflammation in vitro and atherosclerosis development in vivo. Our study suggests that the anticancer drug SAHA could be repurposed as an effective therapeutic agent for atherosclerosis.
Materials and Methods

Reagents
The library of small-molecule drugs (NCI Spectrum Compound Library 2400 chemical compounds dissolved at 1 mmol/L in DMSO) was purchased from the University of Rochester Pathway Discovery Resource. SAHA was purchased from L C Laboratories (#V-8477, purity >99%; Woburn, MA). iQ SYBR Green Supermix (#1708886) was purchased from Bio-Rad Laboratories (Hercules, CA 
Transfection and Luciferase Assay
COS-7 cells plated in 100-mm dishes were transfected with 5.4 lg of KLF2-Luc using Lipofectamine 2000 in Opti-MEM (Gibco, Grand Island, NY). After 6 hours of transfection, the transfected cells were then plated in 96-well plates at a density of 3.5910 5 cells/well in normal DMEM containing 10% FBS (100 lL/well). When cells were attached to the bottom of plate, the drugs (1.0 lL/well; final concentration was 5 lmol/ L, 200 lL medium/well) were added into the 96-well plate for 24 hours. Activity of the luciferase reporter gene was assayed using Dual-Luciferase Reporter Assay System (Promega, Madison, WI) and detected using a microplate spectrophotometer (BMG Labtech, Ortenberg, Germany). The fold of KLF2 activity of the tested compound is calculated as compound firefly luciferase value/DMSO firefly luciferase value.
Real-Time PCR
Total RNA was extracted from cultured HCAECs and lung ECs using an RNeasy Mini kit (Qiagen, Hilden, Germany). 18 In brief,
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cells were plated in 24-well plates and treated with SAHA (0.1, 1, and 10 lmol/L) for 24 hours. After treatment, cells were washed with PBS. Total RNA was extracted using a QIAGEN RNeasy Mini kit (Qiagen). Mouse aorta EC RNA was extracted using QiaZol lysis reagent (Qiagen). 19 Quantitative real-time PCR was performed using iQ SYBR Green Supermix (Bio-Rad) in a BioRad iQ5 real-time PCR thermal cycler. Relative mRNA expression of target genes was normalized to the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase, and expressed as fold change over control. 20, 21 Sequences of the specific mouse primers were designed using IDT PrimerQuest software, and the oligo sequences are listed in Table S1 .
Western Blot
Western blot was performed as previously described. 18 
Assay of Monocyte Adhesion to ECs
Assay of monocyte adhesion to ECs were essentially performed as previously described. [22] [23] [24] [25] In brief, confluent
HCAECs were plated in 6-well plates the day before pretreatment with vehicle (0.1% DMSO) or SAHA (10 lmol/L) of indicated concentrations for 12 hours. TNFa (at a final concentration of 10 ng/mL) was added and incubated in a CO 2 incubator for 6 hours. Then, 5 to 7910 6 of the THP-1 cells were added to the HCAECs in a final volume of 2.5 mL and incubated in a CO 2 incubator for 30 minutes. After treatment, cells were gently washed 3 times with serum-free medium to remove nonadherent THP-1 cells from the plate. Phase-contrast microphotographs of cells were taken using a Canon A640 digital camera with a Zeiss Axiovert 40C microscope (Carl Zeiss, Jena, Germany). Numbers of adherent cells from each image were counted and plotted.
Approval of Animal Studies
All animal procedures conformed to the Guideline for the Care and Use of Laboratory Animals published by the NIH and were approved by the Institutional Animal Care and Use Committee of the University of Rochester Medical Center (Rochester, NY).
Isolation of Mouse Lung ECs
KLF2 +/À mice (B6; 129S4-Klf2 tm1.1Hhn /J, Stock# 026926) were purchased from JAX Laboratory (Bar Harbor, ME). Mouse lung ECs were isolated as described previously. 26 Briefly, lungs from 3 mice of each group were minced into pieces and digested with prewarmed type I collagenase (2 mg/mL) at 37°C for 45 minutes. The suspension was filtered through a 70-lm disposable cell strainer and then centrifuged at 800 g at 4°C for 5 minutes.
Precipitates were resuspended in cold PBS+BSA+Penicillin/ Streptomycin. The cell suspension was then incubated with CD31 (#553370; BD Pharmingen, San Jose, CA)-coated Dynabeads (Invitrogen, Carlsbad, CA) on a rotor at room temperature for 15 minutes, and then washed until the suspension became visibly clear. Cells with beads were resuspended in growth medium (DMEM+20%FBS+penicillin/ streptomycin+heparin) and plated on 0.1% gelatin-coated culture dishes. At 5 to 9 days after plating, cells approached confluence. A second sort of cells were performed with CD102-coated (#553326; BD Pharmingen) Dynabeads sorting. Then, cells were cultured in growth medium and used for indicated experiments immediately.
TNFa-Stimulated Endothelial Inflammation Assay
Isolated lung ECs from 3 mice of each group were treated with SAHA and TNFa the same as in HCAECs. RNA and protein samples were used for western blot and qPCR experiments. In vivo, SAHA (50 mg/kg/day) or vehicle (0.5% carboxymethyl cellulose-sodium) was orally administered to KLF2 +/+ and KLF2 +/À mice for 10 days. Then, mice were injected with mTNFa (0.5 lg/mouse) for 6 hours. Mice were euthanatized by CO 2 euthanasia. Aortic ECs from 3 mice were pooled by lysed with 19 SDS sample buffer by flushing the vessel lumen. Western blot was performed to detect mouse VCAM1 (#AF643, 1:1000; R&D Systems) and ICAM1 (#AF796, 1:1000; R&D Systems) expression.
Analysis of Atherosclerotic Lesions and Lipid Profile
To evaluate the potential antiatherosclerotic efficacy of SAHA, we administered vehicle (0.5% carboxymethyl cellulosesodium; n=9), or SAHA (50 mg/kg body weight/day, by oral gavage; n=10) into 6-week-old ApoE À/À mice, which were fed a western-type diet (#TD88137; Harlan Teklad, North Easton, MA) for an additional 12 weeks to accelerate plaque formation. After treatment, mice were euthanatized, and whole aorta were isolated, fixed, and subject to en face Oil Red O staining, as previously described. 18 The ratio of Oil Red O-positive lesion area to total lumen area was calculated for each mouse using NIH ImageJ software and expressed as percentage of total area. Serum from vehicle-and SAHA-treated mice (n=8/each group) was prepared at the end point, and levels of total cholesterol, triglyceride, low-density-lipoprotein cholesterol/very-low-density-lipoprotein cholesterol were analyzed with commercial colorimetric kits from BioVision, Inc. (#K622, #K613; Milpitas, CA). After reaction, absorbance at 562 nm was recorded and lipid concentration was calculated using total cholesterol and triglyceride standard curves. One microliter of undiluted serum was used for measuring total cholesterol, 2 lL of undiluted serum for measuring triglyceride, and 2 lL of diluted serum for measuring low-density-lipoprotein cholesterol/very-low-density-lipoprotein cholesterol (and multiply dilution factor). We designed a high-throughput compound screening method using a human À1.7-kb KLF2-luc in COS-7 cells. To verify our screening system, we first tested the responsiveness of reporter vectors to reported compounds (simvastatin 10, 12 ) that activated KLF2 or KLF2-upstream activators (dual specificity mitogen-activated protein kinase kinase 5 27 and MEF2 22 ). As shown in Figure S1 , compared with control treatment (DMSO or Ad-lacZ), simvastatin, adenoviral dual specificity mitogen-activated protein kinase kinase 5, and MEF2 infection could dramatically increase KLF2 luciferase activity in COS-7 cells transfected with KLF2-luc plasmid. These data demonstrated that KLF2-luc screening model was successfully established and could be used for subsequent screening of potential KLF2 activators. The Spectrum library is a small collection of 2400 compounds that contains natural products (25%), marketed drugs (in the United States, Europe, and Japan, 60%) and other bioactive compounds (15%). Among the 2400 compounds tested, 25 compounds were discovered to increase KLF2-luc activity ≥2-fold ( Figure 1A) . Among the 25 positive-hit compounds, known KLF2-activating compounds, including simvastatin, rosuvastatin, mevastatin, atorvastatin, and resveratrol, were identified and labeled ( Figure 1A) . These results further validated the successful establishment of our KLF2-luc screening system.
Statistical Analysis
One of the hit drugs we have identified is SAHA ( Figure 1B) , a US Food and Drug Administration-approved anticancer drug. In our system, SAHA could significantly increase KLF2 promoter luciferase activity ( Figure 1A ) more than 50-fold compared with vehicle control. We next evaluated the effect of SAHA on KLF2 expression in HCAECs. Our qPCR assay indicated that SAHA could increase KLF2 mRNA expression at 10 lmol/L ( Figure 1C) . Meanwhile, SAHA (10 lmol/L) also significantly decreased the mRNA expression of known KLF2-target gene endothelin-1 28, 29 ( Figure S2 ).
Taken together, our data suggest that SAHA is a bona-fide KLF2 activator.
To identify the mechanism for SAHA-mediated activation of the KLF2 promoter, we performed dual-luciferase activity assay by transfecting COS7 cells with wild-type, KLF2-promoterdriven luciferase reporter plasmid (À221 bp, KLF2-221-wt) and mutant plasmids with point mutation in the MEF2 binding site of the KLF2 promoter region (gifted by Prof Mukesh Jain, 10 KLF2-221-mutant). Transfected cells were incubated with or without SAHA for 24 hours, then luciferase activity was determined. We observed that mutation of the MEF2 binding site significantly reduced the SAHA-mediated increase of the KLF2 promoter activity ( Figure 1D ). These data implicate that SAHA induces the KLF2 promoter activity through MEF2 binding.
SAHA Exhibited Anti-Inflammatory Effects and Attenuated Monocyte Adhesion to ECs
KLF2 is a potent anti-inflammatory transcription factor that maintains normal endothelial function. 5 To determine whether SAHA-mediated KLF2 upregulation improves EC function, the effect of SAHA on TNFa-induced monocyte adhesion to HCAECs was evaluated. Our data showed that, at concentrations of 0.1 to 10 lmol/L, SAHA did not significantly affect EC viability ( Figure S3 ). Compared with the vehicle control, TNFa-induced THP-1 monocyte adhesion to HCAECs was greatly blocked by SAHA (Figure 2A and 2B) . To investigate the mechanism by which SAHA attenuates monocyte adhesion to ECs, expression of KLF2 and adhesion molecules including VCAM1 and ICAM1 were examined. Figure 3A shows that TNFa significantly increased VCAM1 and ICAM1 mRNA expression. Figure 3B shows that TNFa increased VCAM1 and ICAM1 protein expression. However, SAHA treatment significantly decreased TNFa-induced VCAM1 (but not ICAM1) mRNA. SAHA treatment significantly decreased TNFainduced VCAM1 and ICAM1 protein expression ( Figure 3A and 3B). Figure 3A shows that TNFa decreased KLF2 mRNA expression whereas SAHA significantly increased KLF2 expression in the presence or absence of TNFa. We also show that adenoviral KLF2 overexpression blocked TNFa-induced VCAM1, but not ICAM1, expression in ECs ( Figure S4 ). Taken together, these data demonstrated that SAHA had a potent antiinflammatory effect in ECs.
Anti-Inflammatory Effects of SAHA Is KLF2 Dependent
To test whether the anti-inflammatory effects of SAHA is KLF2 dependent, we evaluated vascular inflammation markers in KLF2-deficient mice treated with SAHA. A previous study has shown that systemic knockout of KLF2 was embryonically lethal 16 ; therefore, in this study, KLF2 +/À mice were used to validate KLF2 dependency of SAHA. Genotypes of KLF2 +/+ and KLF2 +/À mice were confirmed by PCR assays ( Figure 4A with DMSO (vehicle) or SAHA (10 lmol/L) for 12 hours. Then, TNFa (10 ng/mL, final concentration) or vehicle (PBS) was added for an additional 3 hours, and then qPCR was performed to assess VCAM1 and ICAM1 mRNA expression. Nonparametric Kruskal-Wallis test; *P<0.05; **P<0.01, n=6. B, HCAECs were treated as described above, and then western blot assays were performed to examine VCAM1 and ICAM1 protein expression. Representative images are shown, and the protein levels of VCAM1 and ICAM1 were normalized to GAPDH. One-way ANOVA with post-hoc Bonferroni test; *P<0.05; **P<0.01, n=5. GAPDH indicates glyceraldehyde 3-phosphate dehydrogenase; ICAM1, intercellular adhesion molecule 1; KLF2, Kruppel-like factor 2; SAHA, suberoylanilide hydroxamic acid; TNFa, tumor necrosis factor alpha; VCAM1, vascular cell adhesion molecule 1.
this inhibitory effect of SAHA was reversed in KLF2 +/À lung and aortic ECs ( Figure S5 ). After observing the anti-inflammatory effects of SAHA was KLF2 dependent, we asked whether KLF2 depletion by siRNA ( Figure S6 ) could partially reverse SAHA-mediated inhibitory effects on monocyte adhesion to ECs. Human umbilical vein ECs were treated with control siRNA or KLF2 siRNA for 48 hours before the monocyte adhesion assay was performed. We observed that KLF2 depletion partially reversed the effect of SAHA ( Figure 4D ). Taken together, these data demonstrate that the anti-inflammatory effect of SAHA was KLF2 dependent.
Oral Administration of SAHA Reduces Atherosclerosis Development in ApoE
À/À Mice
The KLF2-activating and anti-inflammatory effects of SAHA prompted us to investigate the potential effects of SAHA on the development of atherosclerosis in an ApoE À/À mouse model. Six-week-old male ApoE À/À mice were fed a high-fat diet, concomitantly treated with carboxymethyl cellulosesodium (vehicle) or SAHA (50 mg/kg/day) for 12 weeks by oral gavage. When compared with the vehicle group, SAHA treatment profoundly reduced gross lesion formation in the aortic arch ( Figure 5A ). The whole en face aortas were stained with Oil Red O, and plaque ratios (plaque area/total area) were calculated for each mouse. As shown in Figure 5B and 5C, the average plaque ratio of vehicle group and SAHA group was 10.0% and 6.7% (P<0.01), respectively. Compared with the vehicle group, SAHA treatment significantly inhibited atherosclerotic lesion formation by 33.2% ( Figure 5B and 5C). However, there was no significant change in serum lipid levels between the vehicle-and SAHA-treated groups ( Figure 5D ). Thus, these results indicate that SAHA treatment attenuates atherosclerosis development in ApoE À/À mice independent of lipid levels. 
Discussion
Atherosclerosis, as a chronic inflammatory disease, [30] [31] [32] [33] plays a major role in the pathogenesis of cardiovascular diseases. 34 Therapeutic targeting of different inflammatory pathways might be effective in preventing and treating cardiovascular diseases. [35] [36] [37] The endothelium, as the key regulator of vascular homeostasis, has vasoprotective properties, including anti-inflammatory response and vasodilation. 38 Endothelial dysfunction is regarded as the primary driver of atherosclerotic disease. 39 Previous studies have shown that KLF2 is protective molecule in vascular diseases. 10 Therefore, designing drugs that specifically modulate endothelial KLF2 expression could result in novel therapies to promote vascular health and thus prevent endothelial dysfunction-associated diseases. 12 The aim of this study was designed to identify potential KLF2 activators that have therapeutic potential to treat atherosclerosis. In this regard, our high-throughput drug screening identified dozens of compounds that can increase KLF2 expression/activity. Among these compounds, SAHA, a well-known US Food and Drug Administration-approved drug that is used to treat various cancers, was identified as a KLF2 activator that could limit atherosclerosis by inhibiting vascular inflammation. Our study shows that SAHA is a KLF2 activator that blocks monocyte adhesion to ECs and inhibits the development of atherosclerosis. Based on our in vitro and in vivo data, SAHA reduces monocyte adhesion mainly by inhibiting TNFastimulated upregulation of VCAM1. Because VCAM1 is a well-known target of KLF2, 40 we investigated whether the downregulation of VCAM1 by SAHA is KLF2 dependent. Given that KLF2 overexpression inhibits TNFa-mediated induction of the proinflammatory molecule, VCAM1, 41 in ECs, it is conceivable that the mechanism for the antiatherosclerotic effect of SAHA is partially exerted through KLF2-dependent anti-inflammatory action. The consequent antiatherosclerotic effects accompanying KLF2 upregulation by SAHA may include promoting a set of genes with demonstrated antithrombotic, -inflammatory, and -proliferative functions. 10, 35, 42 SAHA, as a pan-HDAC inhibitor, was approved by the US Food and Drug Administration as an effective anticancer agent. 43 Our recent study has shown that HDAC5 associates with KLF2 and represses KLF2 transcriptional activation. 44 In light of the fact that SAHA is a pan-inhibitor for multiple HDACs, therefore it could conceptually increase expression of many genes by increasing transcriptional accessibility of epigenetic marks to gene promoters. However, the contributory role of SAHA on HDAC isoforms to KLF2 upregulation need to be further elucidated. Although we have shown that SAHA reduces monocyte adhesion under static conditions, it would be important to validate the antiadhesive effects of SAHA in a more physiologically relevant model by applying shear flow and TNFa. 45, 46 We also recognize that atherosclerosis is a complex, chronic inflammatory disease with the functional Figure 5 . SAHA attenuates atherosclerosis development in ApoE interplay among different cell types. 47 Given that KLF2 is expressed in multiple cell types involved in atherosclerosis, 16, 48, 49 including monocyte/macrophage, ECs, smooth muscle cells, and T cells, it is possible that the atheroprotective effects of SAHA observed in ApoE À/À mouse models could result from the combined effects of SAHA on multiple cellular events involved in atherosclerotic lesion formation. Therefore, the specific contribution of different cell types in SAHA-mediated atheroprotection warrants further studies. Consistent with our results, previous studies have shown that Scriptaid or trichostatin A as pan-HDAC inhibitors could successfully prevent neointima formation from balloon injury, 50 and trichostatin A also can attenuate TNFa-induced monocyte adhesion through suppression of VCAM1. 51 Preclinical atherosclerosis models have suggested that drugs modulating histone acetylation may be utilized to treat cardiovascular disease in the future. 52 It is noteworthy that, to date, there are some debates on the effects of HDAC inhibitors in treating experimental atherosclerosis. 50 Moreover, the side effects of HDAC inhibitor on the vascular system need to be systematically and closely monitored. 50 Therefore, HDAC inhibitors with a high efficacy and safety profile might be exploited as promising therapeutic agents of atherosclerotic vascular diseases. In summary, the present study demonstrates that SAHA is a novel KLF2 activator and suggests that the anticancer drug, SAHA, could be repurposed as an effective KLF2-dependent anti-inflammatory and -atherosclerotic drug, which merits further clinical evaluation.
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